RxDoctor Payments Data

Amy Couch, MD

Family Medicine · Washington, MONPI 1275730152

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,962 of the $41,886 with a category attached, or 64.4%. Reprise Biomedical, Inc. accounts for 69.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $25,772 and has fallen 92.2% since, to $2,020 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,886in general payments, 2019–2025

Across 354 payments — averaging $118.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Reprise Biomedical, Inc.$29K
  • Imbed Biosciences Inc.$4K
  • ETS Wound Care LLC$2K
  • Smith+Nephew$1K
  • Organogenesis Inc.$1K
  • Integra Lifesciences Corporation$772
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$26,96264%
  • Travel & lodging$8422%
  • Food & beverage$14,08234%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,886 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$27,780
Medicare patients
61
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.17$14,185
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$167
Ciprofloxacin Hcl12$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,272$14,18517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →